Published in Cancer Res on May 15, 1989
IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis. Mol Cancer Ther (2010) 1.04
Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther (2011) 1.00
Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer (1995) 0.89
Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer. Contemp Oncol (Pozn) (2016) 0.75
Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells. Antioxidants (Basel) (2017) 0.75
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 3.54
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol (1977) 3.03
The pharmacology and clinical uses of tamoxifen. Pharmacol Ther (1984) 3.02
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst (1998) 2.88
A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res (1993) 2.65
Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev (1998) 2.50
Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45
Structure of the mammalian kinetochore. Chromosoma (1981) 2.34
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst (1992) 2.19
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res (1997) 2.12
Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos (1991) 2.04
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst (1990) 1.97
Origin of kinetochore microtubules in Chinese hamster ovary cells. Chromosoma (1980) 1.87
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res (1988) 1.80
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res (1996) 1.79
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res (1990) 1.78
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Biochemical pharmacology of antiestrogen action. Pharmacol Rev (1984) 1.74
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res (2000) 1.73
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Structure of kinetochore fibers: microtubule continuity and inter-microtubule bridges. Chromosoma (1981) 1.64
Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep (1976) 1.63
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med (1991) 1.55
Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. J Biol Chem (1994) 1.53
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res (1987) 1.52
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer (1976) 1.50
Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50
Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat (1982) 1.48
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res (1988) 1.44
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Tamoxifen and contralateral breast cancer. J Am Coll Surg (1999) 1.41
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol (1992) 1.39
Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol (1987) 1.38
Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38
Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep (1981) 1.37
The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34
A risk-benefit assessment of tamoxifen therapy. Drug Saf (1993) 1.34
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol (2005) 1.31
Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat (1988) 1.29
Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol (1976) 1.27
Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer (1980) 1.27
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res (1982) 1.25
An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res (1995) 1.23
High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol (1989) 1.21
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res (1988) 1.19
Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem (1988) 1.19
Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat. Mol Cell Endocrinol (1977) 1.18
Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res (1989) 1.17
Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol (1980) 1.16
Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res (1991) 1.16
Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett (1995) 1.16
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
Structure-activity relationships of estrogens. Environ Health Perspect (1985) 1.15
An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest (1996) 1.14
Streptovaricins inhibit focus formation by MSV (MLV) complex. Nat New Biol (1971) 1.14
Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Treat (1987) 1.13
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer (2006) 1.13
Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol (1976) 1.12
Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer (1996) 1.12
Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol (1979) 1.09
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08
Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer (1975) 1.06
Reliability of steroid hormone receptor assays: an international study. Eur J Cancer Clin Oncol (1983) 1.06
Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res (1997) 1.06
Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J Immunol (1978) 1.05
Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol Pharmacol (1990) 1.05
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol (1996) 1.05
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst (1992) 1.04
Aquanititave semimicro, semiautomated colorimetric assay for interferon. J Lab Clin Med (1977) 1.04
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res (1992) 1.04
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med (1982) 1.03
Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus. Nat New Biol (1971) 1.03
Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer (2000) 1.03
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene (2007) 1.03
Binding of [3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol Cell Endocrinol (1977) 1.03
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med (1992) 1.03
Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem (1996) 1.02
Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc (1987) 1.02